Dr. Luko Michael Laptalo, MD

Dr. Laptalo practices at Mercy Medical Group, A Service Of Dignity Health Medical Foundation in Carmichael, California.

Dr. Laptalo's NPI, 1114958501, was assigned on July 5, 2006. Dr. Laptalo graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 1995. Dr. Laptalo holds California license A66405.

Dr. Laptalo's primary practice is Mercy Medical Group, A Service of Dignity Health Medical Foundation, at 6511 Coyle Ave, Carmichael, CA 95608-0306. The practice phone is (916) 556-3300.

Dr. Laptalo's primary practice is Mercy Medical Group, A Service Of Dignity Health Medical Foundation in Carmichael, California. Dr. Laptalo is also affiliated with Dignity Health - Mercy San Juan Medical Center. The medical group on file is Mercy Medical Group. Dmand AI also links Dr. Laptalo to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Laptalo practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Laptalo's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Laptalo is board certified in hematology by the American Board of Internal Medicine. Dr. Laptalo is licensed in California.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Laptalo treats.

CMS data shows 7,008 Medicare services from Dr. Laptalo across 24 procedure codes in 2024, for 571 Medicare patients. Medicare paid $210,688 for them.

CMS counts 571 Medicare patients who saw Dr. Laptalo in 2024. The largest group is 65 to 74, with 231 patients. 74% of them have high blood pressure, and 70% have high cholesterol. 25% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Laptalo's median patient age at 66, with 67% women.

In 2024, Dr. Laptalo wrote 1,869 Medicare Part D claims for 284 patients. 78% of them were for generic drugs. CMS names the drug for 1,582 of them, across 48 drugs with 11 or more claims each, at $3,980,205 in total drug cost. In 2023, CMS named 1,475 claims across 45 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Laptalo for performance year 2024, reported through an alternative payment model (APM). Dr. Laptalo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Laptalo as offering telehealth.

Dmand AI links 2 papers to Dr. Laptalo. The most frequent topics are Adenocarcinoma, Bronchiolo-Alveolar and Lung Neoplasms. Dr. Laptalo has published most often in Clin Lung Cancer. Dr. Laptalo's most frequent co-authors are Derick Hon Man Lau, MD, PhD, Regina Gandour-Edwards, MD and Primo Nery Lara, MD.

CMS Open Payments shows 28 general payments to Dr. Laptalo from 14 drug and device companies from 2016 to 2025. Education make up the largest share, 56% of the total. Janssen Pharmaceuticals, Inc paid the most, $257.

Dr. Laptalo graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 1995.

Dr. Laptalo is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.